Introduction
============

We have already described the difference between cognitive "impairment", and the cognitive "decline" typically observed during aging, and concluded that in hypertensive patients the most commonly involved cognitive domains were long-term memory and executive functioning.[@b1-vhrm-7-281] There is clear evidence that hypertension produces many pathological changes in the vascular system. Because it affects the brain, hypertension is the most important risk factor for stroke.[@b2-vhrm-7-281] Apart from this complication, however, high blood pressure may damage the brain blood vessels, cause white matter lesions, and lead to both cortical and subcortical volume loss. These conditions may cause cognitive impairment, vascular dementia and, in some cases, even contribute to the progression of Alzheimer′s disease. Due to the long-term subclinical nature of these conditions, it is essential to use neuropsychological tests to study them.[@b3-vhrm-7-281],[@b4-vhrm-7-281] The increasing interest in the prevention, early detection, and management of cognitive impairment is the foundations of our investigation. The aims of this study were to observe the cognitive evolution, initially impaired, in our sample of hypertensive patients for 6 years, and to correlate our results with the blood pressure values (achieved therapeutic goals) and anti-hypertensive medications used.

Materials and methods
=====================

During the recruitment phase for 5 months, between December 2001 and April 2002, all patients seen in the outpatient cardiology clinic of the Hospital Español in Buenos Aires, Argentina, were invited to participate in the trial if they met the inclusion criteria. Both male and female patients ≥65 years of age with a hypertension diagnosis were included in this study. Individuals with a history of neurologic disease (stroke, transitory ischemic attack), psychiatric disease (depression or dementia according to the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV),[@b5-vhrm-7-281] metabolic disease, diabetes mellitus (according to the standard of the American Diabetes Association),[@b6-vhrm-7-281] dislipemia (defined as the use of cholesterol-lowering drugs, low-density lipoprotein \>160 mg/dL, or nonhigh-density lipoprotein \>190 mg/dL), and cardiovascular disease (heart failure, atrial fibrillation and cardiac surgery), as well as those on cholinesterase inhibitors, glutamatergic or antipsychotic inhibitors, were excluded. Sixty caucasian patients out of 520 consecutive patients signed an informed consent to participate in a 6-year follow-up trial. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg at office visit and/or on three occasions throughout their clinical history or if they were taking specific antihypertensive medication. Blood pressure (BP) was measured according to both national and international guidelines,[@b7-vhrm-7-281],[@b8-vhrm-7-281] together with each cognitive evaluation. The anti-hypertensive medication was not modified during follow-up. Other clinical conditions (cardiac diseases, cerebral diseases, etc) were recorded. In the benzodiazepine-treated group, benzodiazepine was discontinued 72 hours before each cognitive evaluation. The trial was approved by an Independent Ethics Committee (IEC), pursuant to international Good Clinical Practice (GCP), the local regulations, and the Declaration of Helsinki and its amendments.

The neuropsychological assessment battery used in our Center included the following test: a) Folstein's Mini Mental Statement Examination (MMSE)[@b9-vhrm-7-281] cut-off point 24,[@b10-vhrm-7-281] b) New York University (NYU) Paragraph Test to evaluate both short and long-term memory,[@b11-vhrm-7-281] c) Trial Making Test[@b12-vhrm-7-281] parts A and B (TMT A and B), d) the clock drawing test,[@b13-vhrm-7-281] e) Stroop Test (Colors and Words),[@b14-vhrm-7-281] and g) before each assessment patients answered a "Hospital Anxiety-Depression Scale" (HAD) questionnaire to evaluate whether the anxiety and/or depression -- two conditions that alter the cognitive results -- were present.[@b15-vhrm-7-281] These tests were administered by neuropsychologists at the beginning of the study and then every 2 years.

Study design and statistics
===========================

This is an observational, cohort, 6-year follow up study. The SPSS 17.0 statistic package was used. While the categorical variables are expressed in percentages, the continuous variables are expressed with mean ± standard deviation (SD). For paired samples, the *t*-test was used. For analysis of variance, ANOVA was used, either parametric or nonparametric Kruskall--Wallis when the distribution was not gaussian or the test used points. The statistical tests were performed for a significance level \<0.05.

Results
=======

The general baseline characteristics of the group, blood pressure, schooling, age (72.5 ± 4.2 years) and the proportion of patients by gender (women 56.6% vs 65%), were included in [Table 1](#t1-vhrm-7-281){ref-type="table"}. After 6 years of follow-up, the average age of the hypertensive patients was 77.9 ± 4.6 years. At the time of enrollment 28.3% of the hypertensive patients were not controlled and hypertension had been present for 10.2 ± 8.2 (range, 5--30) years. The evolution of the cognitive domains studied (average ± SD) after 76.4 ± 2.8 months of follow-up is shown in [Table 2](#t2-vhrm-7-281){ref-type="table"}. During follow-up, 2 patients were lost to follow up (3.3%) and 8 patients died (13.3%) ([Table 3](#t3-vhrm-7-281){ref-type="table"}). Three patients developed dementia (density incidence 0.6% pt/y) and were excluded from the following neuropsychological tests. The depression density incidence was 1.6% pt/y (n = 12). Patients with depression were treated and none had clinical signs at the time of evaluation. Memory impairment both in the short and long term remained unchanged during follow-up (baseline short-term memory 4 ± 2.1 vs final short-term memory 5 ± 2.4, pt = ns; basal long-term memory 6 ±2.5 vs final long-term memory 6 ±2.8, pt = ns). Throughout follow-up the results of the MMSE were normal (baseline 28 ± 1.6 vs final points 29 ± 2.2, pt = ns). A more marked impairment was observed in tests evaluating executive function. Performance in the Stroop test decreased throughout the follow-up showing more interference (basal results −0.6 ± 5.8 vs final results −2.3 ± 8.6, *P* = 0.031) ([Figure 1](#f1-vhrm-7-281){ref-type="fig"}). The capacity to perform TMT part B progressively decreased showing statistical significance at 4 years compared with the basal result (16.6% \[n = 10\] vs 38.2% (n = 18), pt = 0.033), whereas after 6 years the downward tendency was (16.6% \[n = 10\] vs 34% \[n = 16\], pt = 0.061) ([Figure 2](#f2-vhrm-7-281){ref-type="fig"}). The results of the cognitive tests showed no relationship with SBP or DBP values or pulse pressure (PP). The antihypertensive treatment was not modified by the investigators. When compared the cognitive performance with the different classes of antihypertensive drugs, used in monotheraphy or combined therapy, no differences were shown.

Discussion
==========

The relationship between the vascular damage caused by hypertension in brain structures, and the development of cognitive disorders and/or dementia several years later, has been widely investigated in epidemiological longitudinal studies.[@b16-vhrm-7-281]--[@b23-vhrm-7-281] However, not all cognitive domains are equally affected by hypertension. In previous observations we showed that the executive functions related to the prefrontal cortex in hypertensive patients were more affected than those of patients with normal blood pressure.[@b1-vhrm-7-281]

The vulnerability to hypoxia and cerebral hypoperfusion is not homogenous in all regions of the brain.[@b24-vhrm-7-281] The frontal lobes -- particularly the prefrontal cortex -- are more vulnerable to aging and even more to the effects of hypertension because of their phylogenetically younger structures.[@b25-vhrm-7-281]

A study of frontal function in hypertensive nonhuman primates (rhesus *Macaque mulatta* monkeys) concluded that in this model of cerebral vascular damage, the abstraction capacity and the executive function were both altered compared with frontal function in nonhypertensive monkeys.[@b26-vhrm-7-281] Sabatini et al observed that anti-hypertensive treatment with different calcium antagonists increased the cellularity of all layers of the prefrontal cortex in spontaneously hypertensive rats (SHR).[@b27-vhrm-7-281]

The frontal lobes, representing 29% of the cortex and the most advanced functions of the brain, called executive functions, depend on the integrity of this lobes.[@b28-vhrm-7-281] Three-way circuits connecting the frontal lobes with the subcortex structures and clinical behavioral syndromes depend on the damaged circuit.[@b29-vhrm-7-281] In our study, the hypertensive patients showed a progressive impairment of executive function during the years studied, reflected by means of the TMT-B and the Stroop test.

The activity of the frontal lobes is strictly related to blood flow.[@b30-vhrm-7-281] These regional brain flow changes are clearly visible in hypertensive patients, which affects their cognitive performance; it seems that, with the passing of time, the duration of hypertension contributes significantly to these changes.[@b24-vhrm-7-281],[@b31-vhrm-7-281] However, in the same way that the loss of secondary vasomotor capacity in hypertensive disorders leads to the redistribution of blood flow as a mechanism of adaptation, cognitive activities also use these mechanisms in order to perform complex activities with limited blood flow. Likewise, cognitive deficits are difficult to detect using conventional tests and subclinical disorders occur within years. This may explain why the MMSE, a low sensitivity and low specificity though useful test, did not change during follow-up. Consequently we had to use specific tests able to detect failure in executive functions.

On the other hand, the basal long-term memory impairment did not show a negative evolution during follow-up, despite being one of the first cognitive domains involved and it is the most common chief complaint in this type of patients.[@b32-vhrm-7-281]

A possible hypothesis for these associations in hypertensive patients is probably due to the direct consequences of the demyelinization (caused by hypoxia and consecutive ischemia),[@b23-vhrm-7-281] and may cause the "disconnection" of subcortical--cortical loops.[@b33-vhrm-7-281],[@b34-vhrm-7-281] This lack of communication between the dorsolateral prefrontal cortex and the nuclei of the base by means of the caudate nucleus may be responsible for the "executive dysfunction".

Depression is a common and under diagnosed symptom in elderly people, characterized mainly by cognitive symptoms (including slow thinking and volition-affected behaviour), which depend on the integrity of the frontal lobes and make the mind rigid.[@b35-vhrm-7-281] However, the density incidence for depression is within the expected range in patients \>65 years old (1.6% pt/y),[@b36-vhrm-7-281] whereas the incidence density for dementia doubled compared with the general population (0.6% pt/y). Many of the cohorts studied have no selective screening for cardiovascular diseases that may appear as confounders or disparities related to the schooling. Our cohort though small has been carefully classified and followed for a reasonable time in order to observe cognitive changes.

Lastly, the blood pressure values during follow-up show a group of well-controlled patients, despite the fact that cognitive impairment grew worse and, although the sample is small no differences were observed in cognitive tests when analyzing patients according to BP values divided into controlled (≤139 and/or ≤89 mmHg) and noncontrolled (≥140 and/or ≥90 mmHg). This result also shows the need to do systematic neuropsychological screening when hypertensive patients are clinically examined so as to detect a possibly very narrow "window space" to intervene and stop the progression of cognitive impairment. We did not notice any changes in length of time of the disease or class of anti-hypertensive drugs used.

For a long time now, frontal lobes were called silent lobes. It is beyond doubt that hypertension is a risk factor for cognitive impairment, dementia, and/or depression. Both memory and executive functions seem to become impaired more often. The "dys-executive" syndrome (prefrontal domains) appears prematurely and its evolution seems to be progressive compared with memory, which seems to be affected more slowly. The unfavorable cognitive evolution does not seem to be related to the BP values or the antihypertensive treatments.
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###### 

General characteristics of the hypertensive patients

  **Variable**                                                      **Hypertensive patients (n = 60)**                  
  ----------------------------------------------------------------- ------------------------------------ -------------- ------
  Age (y)[^1^](#tfn2-vhrm-7-281){ref-type="table-fn"}               72.5 ± 4.2                                          
  Female                                                            39                                                  65
  Schooling level                                                                                                       
    Grammar school                                                  35                                                  58.3
    High-school                                                     20                                                  33.3
    College studies                                                 5                                                   8.3
  Blood pressure (BP)[^2^](#tfn3-vhrm-7-281){ref-type="table-fn"}                                                       
  Systolic BP                                                                                            141.4 ± 17.8   
  Diastolic BP                                                                                           80.8 ± 9.02    
  Pulse pressure                                                                                         60.5 ± 16.6    
  Obesity[^3^](#tfn5-vhrm-7-281){ref-type="table-fn"}               10                                                  16.6
  Smoking                                                                                                               
    Nonsmokers[^4^](#tfn5-vhrm-7-281){ref-type="table-fn"}          50                                                  83.3
    Smokers                                                         10                                                  16.6
  Cardiopathy                                                                                                           
    Coronary pathology                                              7                                                   11.6
    Arrhythmia[^5^](#tfn6-vhrm-7-281){ref-type="table-fn"}          12                                                  20
  Psychotropics use[^6^](#tfn7-vhrm-7-281){ref-type="table-fn"}     27                                                  45

**Notes:**

Age: years, x ± DE;

BP: mm Hg;

obesity: body mass index ≥30 kg/m;

smoking: had never smoked or had not smoked for more than a year;

arrhythmia: extrasystoles supra and/or ventricular;

psychotropics: benzodiazepines.

###### 

Cognitive evolution during the follow-up

  **Variable**           **Basal (n = 60)**   **2 years (n = 51)**   **4 years (n = 47)**                                    **6 years (n = 47)**   ***P* value**
  ---------------------- -------------------- ---------------------- ------------------------------------------------------- ---------------------- ---------------
  Systolic BP (mm Hg)    140 ± 16.5           140 ± 17.3             146.5 ± 19.9                                            148 ± 21.4             ns
  Diastolic BP (mm Hg)   80 ± 8.4             80 ± 8.6               80 ± 9.8                                                85 ± 8.9               ns
  Pulse pressure         60 ± 15              60 ± 15.6              60 ± 16,8                                               64 ± 18.2              ns
  MMSE                   28 ± 1.6             29 ± 1.0               29 ± 1.1                                                29 ± 2.2               ns
  Short-term memory      4 ± 2.1              5 ± 2.8                4 ± 2.2                                                 5 ± 2.4                ns
  Long-term memory       6 ± 2.5              8 ± 3.8                6 ± 3.0                                                 6 ± 2.8                ns
  TMT-B nonexecution     10 (16.6%)           12 (23.5%)             18 (38.2%)[\*](#tfn9-vhrm-7-281){ref-type="table-fn"}   16 (34.0%)             = 0.061
  Stroop test            −0.6 ± 5.8           −0.9 ± 5.9             −1.2 ± 6.6                                              −2.3 ± 8.6             = 0.013

**Note:**

*P* = 0.033 vs baseline.

**Abbreviations:** BP, blood pressure; MMSE, Mini Mental State Examination; TMT-B, Trial Making Test part B.

###### 

Mortality causes

  **Causes**                **N**   **% of total deaths**
  ------------------------- ------- -----------------------
  Cardiac disease                   50
    Heart failure           2       
    Myocardial infarction   1       
    Sudden death            1       
  Stroke                            25
    Cerebral aneurysm       1       
    Cerebral hemorrhage     1       
  Oncologic disease                 25
    Leukemia                1       
    Endometrial cancer      1       
